OPKO Health, Inc. (OPK)
OPK Stock Price Chart
Explore OPKO Health, Inc. interactive price chart. Choose custom timeframes to analyze OPK price movements and trends.
OPK Company Profile
Discover essential business fundamentals and corporate details for OPKO Health, Inc. (OPK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
2 Nov 1995
Employees
3.00K
Website
https://www.opko.comCEO
Phillip Frost
Description
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
OPK Financial Timeline
Browse a chronological timeline of OPKO Health, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Apr 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.04.
Earnings released on 31 Jul 2025
EPS came in at -$0.19 falling short of the estimated -$0.12 by -58.33%, while revenue for the quarter reached $156.81M , missing expectations by -5.96%.
Earnings released on 30 Apr 2025
EPS came in at -$0.10 falling short of the estimated -$0.06 by -66.67%, while revenue for the quarter reached $149.95M , missing expectations by -9.50%.
Earnings released on 27 Feb 2025
EPS came in at $0.01 surpassing the estimated -$0.08 by +112.50%, while revenue for the quarter reached $183.64M , beating expectations by +18.16%.
Earnings released on 7 Nov 2024
EPS came in at $0.03 surpassing the estimated -$0.10 by +130.00%, while revenue for the quarter reached $173.63M , beating expectations by +11.72%.
Earnings released on 7 Aug 2024
EPS came in at -$0.01 surpassing the estimated -$0.09 by +88.89%, while revenue for the quarter reached $182.19M , missing expectations by -1.62%.
Earnings released on 7 May 2024
EPS came in at -$0.12 falling short of the estimated -$0.09 by -33.33%, while revenue for the quarter reached $173.69M , missing expectations by -5.08%.
Earnings released on 27 Feb 2024
EPS came in at -$0.09 matching the estimated -$0.09, while revenue for the quarter reached $181.90M , beating expectations by +2.46%.
Earnings released on 6 Nov 2023
EPS came in at -$0.11 falling short of the estimated -$0.09 by -22.22%, while revenue for the quarter reached $178.60M , beating expectations by +2.19%.
Earnings released on 3 Aug 2023
EPS came in at -$0.03 surpassing the estimated -$0.07 by +57.14%, while revenue for the quarter reached $265.42M , beating expectations by +45.41%.
Earnings released on 3 May 2023
EPS came in at -$0.02 surpassing the estimated -$0.07 by +71.43%, while revenue for the quarter reached $237.60M , beating expectations by +22.89%.
Earnings released on 23 Feb 2023
EPS came in at -$0.11 matching the estimated -$0.11, while revenue for the quarter reached $185.40M , beating expectations by +10.22%.
Earnings released on 8 Nov 2022
EPS came in at -$0.11 falling short of the estimated -$0.10 by -10.00%, while revenue for the quarter reached $179.74M , missing expectations by -2.05%.
Earnings released on 4 Aug 2022
EPS came in at -$0.04 falling short of the estimated -$0.00 by -1.85K%, while revenue for the quarter reached $309.89M , missing expectations by -5.19%.
Earnings released on 9 May 2022
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $329.22M , missing expectations by -1.02%.
Earnings released on 24 Feb 2022
EPS came in at -$0.11 falling short of the estimated -$0.02 by -450.00%, while revenue for the quarter reached $401.30M , beating expectations by +21.67%.
Earnings released on 28 Oct 2021
EPS came in at $0.04 surpassing the estimated $0.02 by +100.00%, while revenue for the quarter reached $385.81M , beating expectations by +29.11%.
Earnings released on 29 Jul 2021
EPS came in at -$0.03 falling short of the estimated -$0.01 by -155.54%, while revenue for the quarter reached $442.41M , meeting expectations.
Earnings released on 28 Apr 2021
EPS came in at $0.05 matching the estimated $0.05, while revenue for the quarter reached $545.17M , beating expectations by +9.27%.
Earnings released on 18 Feb 2021
EPS came in at $0.05 surpassing the estimated $0.04 by +19.05%, while revenue for the quarter reached $494.60M , beating expectations by +14.07%.
Earnings released on 29 Oct 2020
EPS came in at $0.04 falling short of the estimated $0.04 by -9.09%, while revenue for the quarter reached $428.06M , missing expectations by 0.00%.
OPK Stock Performance
Access detailed OPK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.